Integrated Analysis of Exosomal Protein Biomarkers on Alternating Current Electrokinetic Chips Enables Rapid Detection of Pancreatic Cancer in Patient Blood

Jean M. Lewis, Ankit D. Vyas, Yuqi Qiu, Karen S. Messer, Rebekah White, Michael (Mike) Heller

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Pancreatic ductal adenocarcinoma (PDAC) typically has nonspecific symptoms and is often found too late to treat. Because diagnosis of PDAC involves complex, invasive, and expensive procedures, screening populations at increased risk will depend on developing rapid, sensitive, specific, and cost-effective tests. Exosomes, which are nanoscale vesicles shed into blood from tumors, have come into focus as valuable entities for noninvasive liquid biopsy diagnostics. However, rapid capture and analysis of exosomes with their protein and other biomarkers have proven difficult. Here, we present a simple method integrating capture and analysis of exosomes and other extracellular vesicles directly from whole blood, plasma, or serum onto an AC electrokinetic microarray chip. In this process, no pretreatment or dilution of sample is required, nor is it necessary to use capture antibodies or other affinity techniques. Subsequent on-chip immunofluorescence analysis permits specific identification and quantification of target biomarkers within as little as 30 min total time. In this initial validation study, the biomarkers glypican-1 and CD63 were found to reflect the presence of PDAC and thus were used to develop a bivariate model for detecting PDAC. Twenty PDAC patient samples could be distinguished from 11 healthy subjects with 99% sensitivity and 82% specificity. In a smaller group of colon cancer patient samples, elevated glypican-1 was observed for metastatic but not for nonmetastatic disease. The speed and simplicity of ACE exosome capture and on-chip biomarker detection, combined with the ability to use whole blood, will enable seamless "sample-to-answer" liquid biopsy screening and improve early stage cancer diagnostics.

Original languageEnglish (US)
Pages (from-to)3311-3320
Number of pages10
JournalACS Nano
Volume12
Issue number4
DOIs
StatePublished - Apr 24 2018

Fingerprint

biomarkers
electrokinetics
Biomarkers
blood
alternating current
Blood
cancer
Glypicans
chips
proteins
Proteins
Biopsy
Screening
screening
blood serum
blood plasma
Liquids
Microarrays
liquids
antibodies

Keywords

  • biomarkers
  • cancer diagnostics
  • colon cancer
  • exosome
  • glypican-1
  • pancreatic cancer
  • whole blood

ASJC Scopus subject areas

  • Materials Science(all)
  • Engineering(all)
  • Physics and Astronomy(all)

Cite this

Integrated Analysis of Exosomal Protein Biomarkers on Alternating Current Electrokinetic Chips Enables Rapid Detection of Pancreatic Cancer in Patient Blood. / Lewis, Jean M.; Vyas, Ankit D.; Qiu, Yuqi; Messer, Karen S.; White, Rebekah; Heller, Michael (Mike).

In: ACS Nano, Vol. 12, No. 4, 24.04.2018, p. 3311-3320.

Research output: Contribution to journalArticle

Lewis, Jean M. ; Vyas, Ankit D. ; Qiu, Yuqi ; Messer, Karen S. ; White, Rebekah ; Heller, Michael (Mike). / Integrated Analysis of Exosomal Protein Biomarkers on Alternating Current Electrokinetic Chips Enables Rapid Detection of Pancreatic Cancer in Patient Blood. In: ACS Nano. 2018 ; Vol. 12, No. 4. pp. 3311-3320.
@article{9f4a4c17cae946f2b90e835124b6e7da,
title = "Integrated Analysis of Exosomal Protein Biomarkers on Alternating Current Electrokinetic Chips Enables Rapid Detection of Pancreatic Cancer in Patient Blood",
abstract = "Pancreatic ductal adenocarcinoma (PDAC) typically has nonspecific symptoms and is often found too late to treat. Because diagnosis of PDAC involves complex, invasive, and expensive procedures, screening populations at increased risk will depend on developing rapid, sensitive, specific, and cost-effective tests. Exosomes, which are nanoscale vesicles shed into blood from tumors, have come into focus as valuable entities for noninvasive liquid biopsy diagnostics. However, rapid capture and analysis of exosomes with their protein and other biomarkers have proven difficult. Here, we present a simple method integrating capture and analysis of exosomes and other extracellular vesicles directly from whole blood, plasma, or serum onto an AC electrokinetic microarray chip. In this process, no pretreatment or dilution of sample is required, nor is it necessary to use capture antibodies or other affinity techniques. Subsequent on-chip immunofluorescence analysis permits specific identification and quantification of target biomarkers within as little as 30 min total time. In this initial validation study, the biomarkers glypican-1 and CD63 were found to reflect the presence of PDAC and thus were used to develop a bivariate model for detecting PDAC. Twenty PDAC patient samples could be distinguished from 11 healthy subjects with 99{\%} sensitivity and 82{\%} specificity. In a smaller group of colon cancer patient samples, elevated glypican-1 was observed for metastatic but not for nonmetastatic disease. The speed and simplicity of ACE exosome capture and on-chip biomarker detection, combined with the ability to use whole blood, will enable seamless {"}sample-to-answer{"} liquid biopsy screening and improve early stage cancer diagnostics.",
keywords = "biomarkers, cancer diagnostics, colon cancer, exosome, glypican-1, pancreatic cancer, whole blood",
author = "Lewis, {Jean M.} and Vyas, {Ankit D.} and Yuqi Qiu and Messer, {Karen S.} and Rebekah White and Heller, {Michael (Mike)}",
year = "2018",
month = "4",
day = "24",
doi = "10.1021/acsnano.7b08199",
language = "English (US)",
volume = "12",
pages = "3311--3320",
journal = "ACS Nano",
issn = "1936-0851",
publisher = "American Chemical Society",
number = "4",

}

TY - JOUR

T1 - Integrated Analysis of Exosomal Protein Biomarkers on Alternating Current Electrokinetic Chips Enables Rapid Detection of Pancreatic Cancer in Patient Blood

AU - Lewis, Jean M.

AU - Vyas, Ankit D.

AU - Qiu, Yuqi

AU - Messer, Karen S.

AU - White, Rebekah

AU - Heller, Michael (Mike)

PY - 2018/4/24

Y1 - 2018/4/24

N2 - Pancreatic ductal adenocarcinoma (PDAC) typically has nonspecific symptoms and is often found too late to treat. Because diagnosis of PDAC involves complex, invasive, and expensive procedures, screening populations at increased risk will depend on developing rapid, sensitive, specific, and cost-effective tests. Exosomes, which are nanoscale vesicles shed into blood from tumors, have come into focus as valuable entities for noninvasive liquid biopsy diagnostics. However, rapid capture and analysis of exosomes with their protein and other biomarkers have proven difficult. Here, we present a simple method integrating capture and analysis of exosomes and other extracellular vesicles directly from whole blood, plasma, or serum onto an AC electrokinetic microarray chip. In this process, no pretreatment or dilution of sample is required, nor is it necessary to use capture antibodies or other affinity techniques. Subsequent on-chip immunofluorescence analysis permits specific identification and quantification of target biomarkers within as little as 30 min total time. In this initial validation study, the biomarkers glypican-1 and CD63 were found to reflect the presence of PDAC and thus were used to develop a bivariate model for detecting PDAC. Twenty PDAC patient samples could be distinguished from 11 healthy subjects with 99% sensitivity and 82% specificity. In a smaller group of colon cancer patient samples, elevated glypican-1 was observed for metastatic but not for nonmetastatic disease. The speed and simplicity of ACE exosome capture and on-chip biomarker detection, combined with the ability to use whole blood, will enable seamless "sample-to-answer" liquid biopsy screening and improve early stage cancer diagnostics.

AB - Pancreatic ductal adenocarcinoma (PDAC) typically has nonspecific symptoms and is often found too late to treat. Because diagnosis of PDAC involves complex, invasive, and expensive procedures, screening populations at increased risk will depend on developing rapid, sensitive, specific, and cost-effective tests. Exosomes, which are nanoscale vesicles shed into blood from tumors, have come into focus as valuable entities for noninvasive liquid biopsy diagnostics. However, rapid capture and analysis of exosomes with their protein and other biomarkers have proven difficult. Here, we present a simple method integrating capture and analysis of exosomes and other extracellular vesicles directly from whole blood, plasma, or serum onto an AC electrokinetic microarray chip. In this process, no pretreatment or dilution of sample is required, nor is it necessary to use capture antibodies or other affinity techniques. Subsequent on-chip immunofluorescence analysis permits specific identification and quantification of target biomarkers within as little as 30 min total time. In this initial validation study, the biomarkers glypican-1 and CD63 were found to reflect the presence of PDAC and thus were used to develop a bivariate model for detecting PDAC. Twenty PDAC patient samples could be distinguished from 11 healthy subjects with 99% sensitivity and 82% specificity. In a smaller group of colon cancer patient samples, elevated glypican-1 was observed for metastatic but not for nonmetastatic disease. The speed and simplicity of ACE exosome capture and on-chip biomarker detection, combined with the ability to use whole blood, will enable seamless "sample-to-answer" liquid biopsy screening and improve early stage cancer diagnostics.

KW - biomarkers

KW - cancer diagnostics

KW - colon cancer

KW - exosome

KW - glypican-1

KW - pancreatic cancer

KW - whole blood

UR - http://www.scopus.com/inward/record.url?scp=85045874029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045874029&partnerID=8YFLogxK

U2 - 10.1021/acsnano.7b08199

DO - 10.1021/acsnano.7b08199

M3 - Article

C2 - 29570265

AN - SCOPUS:85045874029

VL - 12

SP - 3311

EP - 3320

JO - ACS Nano

JF - ACS Nano

SN - 1936-0851

IS - 4

ER -